Literature DB >> 17911111

Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.

Ying Wang1, Tip W Loo1, M Claire Bartlett1, David M Clarke2.   

Abstract

The most common cause of cystic fibrosis (CF) is defective folding of a cystic fibrosis transmembrane conductance regulator (CFTR) mutant lacking Phe(508) (DeltaF508). The DeltaF508 protein appears to be trapped in a prefolded state with incomplete packing of the transmembrane (TM) segments, a defect that can be repaired by expression in the presence of correctors such as corr-4a, VRT-325, and VRT-532. To determine whether the mechanism of correctors involves direct interactions with CFTR, our approach was to test whether correctors blocked disulfide cross-linking between cysteines introduced into the two halves of a Cys-less CFTR. Although replacement of the 18 endogenous cysteines of CFTR with Ser or Ala yields a Cys-less mutant that does not mature at 37 degrees C, we found that maturation could be restored if Val(510) was changed to Ala, Cys, Ser, Thr, Gly, Ala, or Asp. The V510D mutation also promoted maturation of DeltaF508 CFTR. The Cys-less/V510A mutant was used for subsequent cross-linking analysis as it yielded relatively high levels of mature protein that was functional in iodide efflux assays. We tested for cross-linking between cysteines introduced into TM6 and TM7 of Cys-less CFTR/V510A because cross-linking between TM6 and TM7 of P-glycoprotein, the sister protein of CFTR, was inhibited with the corrector VRT-325. Cys-less CFTR/V510A mutant containing cysteines at I340C(TM6) and S877C(TM7) could be cross-linked with a homobifunctional cross-linker. Correctors and the CFTR channel blocker benzbromarone, but not P-glycoprotein substrates, inhibited cross-linking of mutant I340C(TM6)/S877C(TM7). These results suggest that corrector molecules such as corr-4a interact directly with CFTR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911111     DOI: 10.1074/jbc.C700175200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR.

Authors:  Andrei A Aleksandrov; Pradeep Kota; Liying Cui; Tim Jensen; Alexey E Alekseev; Santiago Reyes; Lihua He; Martina Gentzsch; Luba A Aleksandrov; Nikolay V Dokholyan; John R Riordan
Journal:  J Mol Biol       Date:  2012-03-08       Impact factor: 5.469

Review 2.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

3.  Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening.

Authors:  Ori Kalid; Martin Mense; Sharon Fischman; Alina Shitrit; Hermann Bihler; Efrat Ben-Zeev; Nili Schutz; Nicoletta Pedemonte; Philip J Thomas; Robert J Bridges; Diana R Wetmore; Yael Marantz; Hanoch Senderowitz
Journal:  J Comput Aided Mol Des       Date:  2010-10-26       Impact factor: 3.686

4.  Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures.

Authors:  Deborah M Cholon; Wanda K O'Neal; Scott H Randell; John R Riordan; Martina Gentzsch
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-11       Impact factor: 5.464

5.  The CFTR Corrector, VX-809 (Lumacaftor), Rescues ABCA4 Trafficking Mutants: a Potential Treatment for Stargardt Disease.

Authors:  Qiangni Liu; Inna Sabirzhanova; Emily Anne Smith Bergbower; Murali Yanda; William G Guggino; Liudmila Cebotaru
Journal:  Cell Physiol Biochem       Date:  2019

6.  Changes in accessibility of cytoplasmic substances to the pore associated with activation of the cystic fibrosis transmembrane conductance regulator chloride channel.

Authors:  Yassine El Hiani; Paul Linsdell
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

7.  Clinical and molecular characterization of S1118F-CFTR.

Authors:  Himabindu Penmatsa; Carla A Frederick; Sunitha Nekkalapu; Veronica G Conoley; Weiqiang Zhang; Chunying Li; John Kappes; Dennis C Stokes; Anjaparavanda P Naren
Journal:  Pediatr Pulmonol       Date:  2009-10

8.  Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.

Authors:  Owen M Woodward; Deepali N Tukaye; Jinming Cui; Patrick Greenwell; Leeza M Constantoulakis; Benjamin S Parker; Anjana Rao; Michael Köttgen; Peter C Maloney; William B Guggino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

9.  The V510D suppressor mutation stabilizes DeltaF508-CFTR at the cell surface.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  Biochemistry       Date:  2010-08-03       Impact factor: 3.162

10.  Interplay between ER exit code and domain conformation in CFTR misprocessing and rescue.

Authors:  Gargi Roy; Elaine M Chalfin; Anita Saxena; Xiaodong Wang
Journal:  Mol Biol Cell       Date:  2009-12-23       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.